Pros and Cons of Genus plc in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | -1.340% | 7.971% | -3.247% | 55.208% | 1.361% | -2.742% | -49.060% |
| United Therapeutics | -0.670% | 0.368% | 7.696% | 83.284% | 14.954% | 129.963% | 187.251% |
| Ligand Pharmaceuticals | -1.680% | -1.676% | -2.222% | 93.407% | 6.024% | 162.687% | 35.333% |
| Ionis Pharmaceuticals Inc. | 0.670% | 0.740% | 0.616% | 157.267% | -3.885% | 102.417% | 83.638% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat